Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 27

1.

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J; United States Drug Induced Liver Injury Network.

Gastroenterology. 2015 Jun;148(7):1340-52.e7. doi: 10.1053/j.gastro.2015.03.006. Epub 2015 Mar 6.

2.

Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction.

[No authors listed]

Med Lett Drugs Ther. 2014 May 12;56(1442):37-8. No abstract available.

PMID:
24818838
3.

Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.

Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, Dávalos M, Méndez-Sánchez N, Arrese M, Schinoni M, Lucena MI, Andrade RJ.

Ann Hepatol. 2014 Mar-Apr;13(2):231-9. Review.

4.

Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S.

Gastroenterology. 2013 Jun;144(7):1419-25, 1425.e1-3; quiz e19-20. doi: 10.1053/j.gastro.2013.02.006. Epub 2013 Feb 16.

PMID:
23419359
5.

Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.

Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K.

Ther Adv Urol. 2013 Feb;5(1):35-41. doi: 10.1177/1756287212466282.

6.

Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation.

Lasaponara F, Sedigh O, Pasquale G, Bosio A, Rolle L, Ceruti C, Timpano M, Negro CL, Paradiso M, Abbona A, Segoloni GP, Fontana D.

J Sex Med. 2013 Nov;10(11):2798-814. doi: 10.1111/jsm.12038. Epub 2013 Jan 24.

7.

Avanafil for treatment of erectile dysfunction: review of its potential.

Burke RM, Evans JD.

Vasc Health Risk Manag. 2012;8:517-23. doi: 10.2147/VHRM.S26712. Epub 2012 Aug 29. Review.

8.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.

Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, Trask B, Day WW.

J Sex Med. 2012 Apr;9(4):1122-33. doi: 10.1111/j.1743-6109.2011.02629.x. Epub 2012 Jan 16.

PMID:
22248153
9.

10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.

Lowe G, Costabile RA.

J Sex Med. 2012 Jan;9(1):265-70. doi: 10.1111/j.1743-6109.2011.02537.x. Epub 2011 Oct 24.

PMID:
22023666
10.

Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.

Arif SA, Poon H.

Clin Ther. 2011 Aug;33(8):993-1004. doi: 10.1016/j.clinthera.2011.06.008. Epub 2011 Jul 16. Review.

PMID:
21762988
11.

Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.

Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N; Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1723-9. doi: 10.1164/rccm.201101-0093OC. Epub 2011 Mar 11.

PMID:
21471085
12.

[Cholestatic acute hepatitis induced by tadalafil (Cialis)].

Essaid A, Timraz A.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):e1-2. doi: 10.1016/j.gcb.2010.01.001. Epub 2010 Feb 18. French. No abstract available.

13.

Sildenafil-induced severe cholestatic hepatotoxicity.

Enomoto M, Sakaguchi H, Ominami M, Iwai S, Morikawa H, Tamori A, Kawada N.

Am J Gastroenterol. 2009 Jan;104(1):254-5. doi: 10.1038/ajg.2008.18. No abstract available.

PMID:
19098889
14.

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN).

Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4. doi: 10.1053/j.gastro.2008.09.011. Epub 2008 Sep 17.

15.

Initially obscure hepatotoxicity attributed to sildenafil.

Wolfhagen FH, Vermeulen HG, de Man RA, Lesterhuis W.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):710-2. doi: 10.1097/MEG.0b013e3282f2bbb5.

PMID:
18679077
16.

PDE-5 inhibitors: current status and future trends.

Masson P, Lambert SM, Brown M, Shabsigh R.

Urol Clin North Am. 2005 Nov;32(4):511-25, viii. Review.

PMID:
16291042
17.

Sildenafil-associated hepatotoxicity.

Daghfous R, El Aidli S, Zaiem A, Loueslati MH, Belkahia C.

Am J Gastroenterol. 2005 Aug;100(8):1895-6. No abstract available.

PMID:
16086731
18.
19.

[Probable sildenafil (Viagra) induced acute hepatitis in a patient with no other risk factors].

Balian A, Touati F, Huguenin B, Prevot S, Perlemuter G, Naveau S, Chaput JC.

Gastroenterol Clin Biol. 2005 Jan;29(1):89. French. No abstract available.

20.

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

PMID:
14568893

Supplemental Content

Support Center